Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Using a new approach to developing biomarkers for the very early detection of ovarian cancer, researchers at Rush University Medical Center have identified a molecule in the bloodstream of infertile women that could one day be used to screen for those at high risk for the disease — or even those with early-stage ovarian cancer.

17 Aug 2011

Genetic culprit behind ovarian cancer discovered

A study has revealed that a single fault in a gene that normally helps the body to repair its DNA increases a woman's risk of ovarian cancer six-fold. One in every 11 women who carry the faulty gene is likely to develop ovarian cancer at some point in her life compared with a typical risk of about one in 70 for women in the general population, scientists said.

11 Aug 2011

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

9 Aug 2011

Ovarian cancer gene discovered

A new study finds that around one woman in 70 is at risk of developing ovarian cancer, which claims more than 4,200 lives a year and this could be attributed to a faulty RAD15D gene. The gene raised the risk to one in 11.

8 Aug 2011

Women with RAD51D gene fault more likely to develop ovarian cancer

Cancer Research UK-funded scientists have discovered that women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing ovarian cancer, the most significant ovarian cancer gene discovery for more than a decade, reveals a study in Nature Genetics1 today.

8 Aug 2011

Breastfeeding for up to one year after birth can reduce child mortality, UNICEF says

Breastfeeding from birth to six months or a year can reduce deaths among children under five by 13 percent, a fact UNICEF is highlighting during World Breastfeeding Week, which runs through August 7, the International Business Times reports.

4 Aug 2011

Conference to discuss novel studies that address how inherited genes cause breast cancer

A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer. Research into understanding and treating hereditary breast cancer will be presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

4 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Positive results from combination drug trial for late-stage ovarian cancer

An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results, leading its Indiana University researchers to actively pursue the next step, conducting a larger clinical trial to test the therapy and to see how it compares with existing treatments for ovarian cancer.

3 Aug 2011

Federal appeals court partially reverses ruling in BRCA patents case

In a 2-1 decision, a federal appeals court today partially reversed a lower court's ruling in a case challenging patents on two human genes, BRCA1 and BRCA2, associated with hereditary breast and ovarian cancer. The court ruled that companies can obtain patents on the genes but cannot patent methods to compare those gene sequences.

3 Aug 2011

Hospitals not doing enough to encourage breastfeeding among new mothers: CDC report

According to a report by the U.S. Centers for Disease Control and Prevention (CDC), hospitals are not doing enough to encourage breastfeeding among new mothers.

3 Aug 2011

Scientists design octapeptides to fight drug resistant ovarian cancer cells

Italian and German scientists have designed peptides to target the protein-protein interface of a key enzyme in DNA synthesis crucial for cancer growth. The peptides act by a novel inhibitory mechanism and curb cancer cell growth in drug resistant ovarian cancer cells.

2 Aug 2011

One in four British women at risk of cancer

A cancer charity revealed figures that show that British women are nearly a fifth more likely to develop cancer at some point during their lives than their European counterparts. Most of it is blamed on lifestyle factors such as obesity and alcohol consumption.

31 Jul 2011

Human genes can be patented in U.S. - Court overrules previous ruling

A lower court in the U.S. had earlier ruled that human genes cannot be patented by biotech companies who use them for diagnostic purposes. Now a federal appeals court ruled on Friday that genes can be patented. The Court of Appeals for the Federal Circuit, which specializes in patent cases, said that Myriad Genetics was entitled to patents on two human genes used to predict if women have an increased risk of getting breast and ovarian cancer.

31 Jul 2011

Studies reveal new set of mutations linked with head and neck cancer

Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Lack of genetic screening for cancers

In a new study published Monday in the journal Cancer, it was noted that while genetic testing to check if a woman has the BRCA1 or BRCA2 mutations can be a useful tool for preventing breast cancer and ovarian cancer in some cases, many doctors are not referring patients.

26 Jul 2011

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

Many doctors do not appropriately offer breast and ovarian cancer counseling

A new analysis has found that many doctors report that they do not appropriately offer breast and ovarian cancer counseling and testing services to their female patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to encourage these services for high-risk women and discourage them for average-risk women.

25 Jul 2011